Characteristics | N | % | HPV Positive N (%) | HPV Negative N (%) | p-value |
---|---|---|---|---|---|
Age | 0.361 | ||||
< 65 years old | 44 | 56.4% | |||
≥ 65 years old | 34 | 43.6% | 35 (59.3) | 9 (47.4) | |
Gender | 24 (40.7) | 10 (52.6) | 0.004 | ||
Female | 64 | 82.1 | |||
Male | 14 | 17.9 | 53 (89.8) | 11 (57.9) | |
Degree of Cellular Differentiation | 6 (10.2) | 8 (42.1) | 0.351 | ||
G I | 6 | 7.7 | |||
G II | 58 | 74.4 | 6 (10.2) | 0 (0) | |
G III | 11 | 14.1 | 42 (71.2) | 16 (84.2) | |
G IV | 3 | 3.8 | 8 (13.6) | 3 (15.8) | |
Clinical Stage (UICC) | 3 (5.1) | 0 (0) | 0.031 | ||
I | 5 | 6.4 | |||
II | 47 | 60.3 | 5 (8.5) | 0 (0) | |
IIIA | 16 | 20.5 | 39 (66.1) | 8 (42.1) | |
IIIB | 10 | 12.8 | 8 (13.6) | 8 (42.1) | |
N Stage | 7 (11.9) | 3 (15.8) | 0.354 | ||
Negative | 60 | 76.9 | |||
Positive | 18 | 23.1 | 47 (79.7) | 13 (68.4) | |
T Stage | 12 (20.3) | 6 (31.6) | 0,012 | ||
T1 (≤ 2 cm) | 6 | 7.7 | |||
T2 (> 2 and ≤5 cm) | 30 | 38.5 | 6 (10.2) | 0 (0) | |
T3 (> 5 cm) | 30 | 38.5 | 27 (45.8) | 3 (15.8) | |
T4 (tumour invading adjacent organ) | 12 | 15.4 | 20 (33.9) | 10 (52.6) | |
HPV | 6 (10.2) | 6 (31.6) | NA | ||
16 | 49 | 62.8 | |||
18 | 10 | 12.8 | 49 (62.8) | 0 (0) | |
Negative | 19 | 24.4 | 10 (12.8) | 0 (0) | |
HIV | 19 (24.4) | 0 (0) | 1.000 | ||
Positive | 19 | 24.4 | |||
Negative | 59 | 75.6 | 14 (23.7) | 5 (26.3) | |
P16 | 45 (76.3) | 14 (73.7) | < 0.001 | ||
Positive | 57 | 73.1 | |||
Negative | 19 | 24.4 | 57 (96.6) | 0 (0) | |
Borderline | 2 | 2.6 | 0 (0) | 19 (100.0) | |
Clinical response at 6 months | 2 (3.4) | 0 (0) | < 0.001 | ||
Yes | 47 | 60.3 | |||
No | 31 | 39.7 | 47 (79.7) | 0 (0) | |
TP53 | 12 (20.3) | 19 (100.0) | < 0.001 | ||
Mutated | 21 | 26.9 | |||
Wild type | 57 | 73.1 | 2 (3.4) | 19 (100.0) | |
Total | 78 | 100.0 | 57 (96.6) | 0 (0) |